Cenexi operational turnaround delays
Cenexi faces operational issues including lower productivity, old lines, and regulatory hurdles for product line shifts, which may delay margin recovery.
GLAND / Q3-FY24 / risks
Keep the risk register visible.
Gland Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Cenexi revenue growth may be pushed out
Analyst question highlighted that operational issues could delay the EUR 30-40 million incremental revenue from new programs beyond FY2026.
India business decline
India revenue declined 7% YoY and remains a low-focus market, with limited growth visibility due to DPCO pricing pressures.